Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter

C Pifl, O Hornykiewicz, B Giros and MG Caron

Institute of Biochemical Pharmacology, University of Vienna, Austria.

The uptake and cytotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of the parkinsonism inducing agent 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP), were studied in COS-7 cells transiently transfected with the cloned human noradrenaline and dopamine transporters and in permanently transfected SK-N-MC neuroblastoma cells. MPP+ had a 10- to 20-fold lower K(m) value for the noradrenaline than for the dopamine transporter. In dopamine transporter expressing cells, the maximal transport rate (Vmax) of MPP+, dopamine and noradrenaline was the same, but in noradrenaline transporter expressing cells the Vmax of MPP+ and dopamine was only one- half of the Vmax of noradrenaline. The turnover numbers (Vmax of uptake/maximal binding sites of binding) were 5 times higher for the dopamine transporter (as measured with [3H]dopamine and [3H]-2 beta- carbomethoxy-3 beta-(4-fluorophenyl) tropane than for the noradrenaline transporter (as measured with [3H]noradrenaline and [3H]nisoxetine). In SK-N-MC cells with similar Vmax values for both catecholamines, noradrenaline transporter expressing cells were killed by lower concentrations of MPP+ in the medium than dopamine transporter expressing cells. Desipramine blocked the toxicity of MPP+ toward the noradrenaline transporter, but not the dopamine transporter expressing cells. We conclude that the toxic effect of MPTP at the striatal dopamine system in the MPTP primate model of Parkinson's disease is not correlated with the affinity profile of MPP+ for catecholamine transporters, but rather with the higher turnover number of MPP+ at the dopamine transporter. In contradistinction, the toxicity of MPTP at the noradrenaline neurons in the primate cerebral cortex (Pifl et al., 1991) may involve the higher affinity of MPP+ for the noradrenaline transporter.

Volume 277, Issue 3, pp. 1437-1443, 06/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. Pifl, G. Nagy, S. Berenyi, A. Kattinger, H. Reither, and S. Antus Pharmacological Characterization of Ecstasy Synthesis Byproducts with Recombinant Human Monoamine Transporters J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 346 - 354. [Abstract] [Full Text] [PDF]

				J. W. Schwartz, G. Novarino, D. W. Piston, and L. J. DeFelice Substrate Binding Stoichiometry and Kinetics of the Norepinephrine Transporter J. Biol. Chem., May 13, 2005; 280(19): 19177 - 19184. [Abstract] [Full Text] [PDF]

				H. H. Sitte, B. Hiptmair, J. Zwach, C. Pifl, E. A. Singer, and P. Scholze Quantitative Analysis of Inward and Outward Transport Rates in Cells Stably Expressing the Cloned Human Serotonin Transporter: Inconsistencies with the Hypothesis of Facilitated Exchange Diffusion Mol. Pharmacol., April 16, 2001; 59(5): 1129 - 1137. [Abstract] [Full Text]

				A. Raz, E. Vaadia, and H. Bergman Firing Patterns and Correlations of Spontaneous Discharge of Pallidal Neurons in the Normal and the Tremulous 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Vervet Model of Parkinsonism J. Neurosci., November 15, 2000; 20(22): 8559 - 8571. [Abstract] [Full Text] [PDF]

				D. S. Goldstein, C. Holmes, S.-T. Li, S. Bruce, L. V. Metman, and R. O. Cannon III Cardiac Sympathetic Denervation in Parkinson Disease Ann Intern Med, September 5, 2000; 133(5): 338 - 347. [Abstract] [Full Text] [PDF]

				P. Scholze, J. Zwach, A. Kattinger, C. Pifl, E. A. Singer, and H. H. Sitte Transporter-Mediated Release: A Superfusion Study on Human Embryonic Kidney Cells Stably Expressing the Human Serotonin Transporter J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 870 - 878. [Abstract] [Full Text]

				N. C. E. Smith and R. Levi LLC-PK1 Cells Stably Expressing the Human Norepinephrine Transporter: A Functional Model of Carrier-Mediated Norepinephrine Release in Protracted Myocardial Ischemia J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 456 - 463. [Abstract] [Full Text]

				C. Pifl and E. A. Singer Ion Dependence of Carrier-Mediated Release in Dopamine or Norepinephrine Transporter-Transfected Cells Questions the Hypothesis of Facilitated Exchange Diffusion Mol. Pharmacol., November 1, 1999; 56(5): 1047 - 1054. [Abstract] [Full Text]

				F. A. Paczkowski, L. J. Bryan-Lluka, P. Pörzgen, M. Brüss, and H. Bönisch Comparison of the Pharmacological Properties of Cloned Rat, Human, and Bovine Norepinephrine Transporters J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 761 - 767. [Abstract] [Full Text]

				S. Apparsundaram, K. R. Moore, M. D. Malone, H. C. Hartzell, and R. D. Blakely Molecular Cloning and Characterization of an L-Epinephrine Transporter from Sympathetic Ganglia of the Bullfrog, Rana catesbiana J. Neurosci., April 15, 1997; 17(8): 2691 - 2702. [Abstract] [Full Text] [PDF]